ARTICLE | Company News
Biopharm, Orquest, Sulzer Medica deal
October 4, 1999 7:00 AM UTC
Biopharm and Orquest will develop Healos/MP52, a bone growth factor product to treat spinal disorders. The product will be based on Biopharm's MP52 recombinant bone inducing cytokine and Orquest's Healos bone graft substitute. Clinical testing of Healos/MP52 is expected to begin in 2000. ...